What is the recommended management for frontotemporal dementia?

Management of Frontotemporal Dementia

No disease-modifying therapies are approved for FTD; management centers on behavioral interventions, symptomatic pharmacotherapy, and multidisciplinary support, while explicitly avoiding cholinesterase inhibitors and memantine. 1

Core Management Principles

What NOT to Use

• Avoid cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine entirely—these medications approved for Alzheimer disease provide no benefit in FTD and can worsen neuropsychiatric symptoms. 1, 2, 3

Pharmacologic Symptom Management

For Behavioral Symptoms

• Selective serotonin reuptake inhibitors (SSRIs) represent the first-line pharmacologic option for behavioral symptoms including disinhibition, apathy, and compulsive behaviors. 3, 4
• Antipsychotics may be considered only for severe agitation that poses safety risks, but use extreme caution due to increased risks of falls, cerebrovascular events, and mortality in dementia patients. 1, 3
• Anti-epileptic medications have limited case report evidence for behavioral control, though side effect concerns limit their routine use. 4

Clinical Pitfall: The majority (approximately 50%) of bvFTD patients initially receive psychiatric diagnoses, resulting in 5–6 year diagnostic delays. 1 This leads to inappropriate psychiatric medication trials that may worsen symptoms or delay proper supportive interventions.

For Motor Symptoms

• For FTD patients who develop motor neuron disease features (FTD-ALS overlap), riluzole is the only FDA-approved medication and should be initiated. 4
• For parkinsonian features (present in 25%–80% of bvFTD patients), a trial of carbidopa-levodopa may be attempted, though response rates are poor compared to idiopathic Parkinson disease. 1, 4

Non-Pharmacologic Interventions (Essential Components)

Therapeutic Services

• Speech-language pathology is essential for managing aphasia variants, apraxia of speech, and dysphagia that develop as disease progresses. 4
• Occupational therapy addresses activities of daily living, safety modifications, and adaptive strategies for executive dysfunction. 4
• Physical therapy maintains mobility and addresses parkinsonian motor features or gait disturbances. 4

Environmental and Behavioral Strategies

• Implement environmental modifications to manage abnormal behaviors—this includes structured routines, reducing overstimulation, and creating safe spaces for compulsive behaviors. 3
• Address safety concerns proactively, including driving cessation, financial management restrictions, and wandering prevention. 1, 5
• Lifestyle modifications should accommodate the patient's altered social cognition, loss of empathy, and disinhibition. 2

Caregiver and Family Support (Critical Priority)

• Caregiver education and support are not adjunctive but central to FTD management, as caregiver burden in FTD exceeds that of other dementias due to behavioral symptoms and younger age of onset. 1, 3, 5
• Provide early counseling on legal issues (advance directives, power of attorney) and financial planning, as executive dysfunction impairs the patient's capacity for these decisions. 3
• Connect families with peer support groups specific to FTD, as the behavioral changes (disinhibition, apathy, loss of empathy) create unique caregiving challenges distinct from Alzheimer disease. 2, 5

Multidisciplinary Care Coordination

• Establish a multidisciplinary team including neurology, psychiatry (for behavioral management), speech-language pathology, occupational therapy, physical therapy, social work, and palliative care. 1
• Coordinate care across specialties, as 20–50% of FTD patients develop cognitive dysfunction and frontotemporal dementia features, and up to 40–50% have behavioral changes requiring psychiatric input. 6

Genetic Counseling and Testing Implications

• Offer genetic counseling and testing for C9orf72, MAPT, and GRN mutations, particularly when family history suggests autosomal-dominant inheritance (20–40% of FTD cases are familial). 1, 7
• C9orf72 testing is especially important when prominent psychiatric features are present, as this mutation can manifest with isolated neuropsychiatric phenotypes years before classic FTD signs. 1
• Genetic testing results inform family planning, enable presymptomatic counseling for at-risk relatives, and may provide access to emerging clinical trials targeting specific genetic mutations. 7, 2

Monitoring Disease Progression

• Serial assessments using the Frontal Behavioral Inventory (FBI) and Stereotypy Rating Inventory (SRI) track behavioral symptom progression. 1
• Repeat neuropsychological testing, particularly social cognition batteries (Ekman 60-Face Test, Mini-SEA), documents cognitive decline trajectory. 1
• Monitor for development of motor features (parkinsonism in 25–80%, motor neuron signs in FTD-ALS overlap) that alter management approach. 1, 6

Emerging Therapies and Clinical Trial Considerations

• Clinical trials are underway targeting specific genetic mutations (C9orf72, MAPT, GRN) and pathological proteins (TDP-43, tau, FUS), including presymptomatic intervention studies. 7, 2
• Refer appropriate patients—particularly those with confirmed genetic mutations and early disease—to specialized FTD centers for clinical trial enrollment. 2

Key Distinction: Unlike Alzheimer disease where symptomatic medications provide modest cognitive benefit, FTD management is entirely supportive and behavioral, with no cognitive-enhancing medications available. 1, 7 The focus must shift from pharmacologic intervention to comprehensive behavioral support, caregiver education, and safety planning from the time of diagnosis. 3, 5